Literature DB >> 20573938

Changes in C-reactive protein levels before type 2 diabetes and cardiovascular death: the Whitehall II study.

A G Tabák1, M Kivimäki, E J Brunner, G D Lowe, M Jokela, T N Akbaraly, A Singh-Manoux, J E Ferrie, D R Witte.   

Abstract

OBJECTIVE: Prospective studies show that high C-reactive protein (CRP) levels predict diabetes and cardiovascular disease (CVD), but changes in this marker preceding disease onset are not well characterized. This study describes CRP trajectories prior to type 2 diabetes onset and fatal CVD.
METHODS: In a prospective cohort of 7350 British civil servants (70% male, mean age 51 years), 558 incident type 2 diabetes cases (75-g oral glucose tolerance test, doctor's diagnosis, or self-report) and 125 certified fatal cardiovascular events were observed during a median follow-up of >14 years. Trajectories of logarithmically transformed CRP levels prior to incident diabetes or fatal cardiovascular event (cases), or the end of follow-up (controls) were calculated using multilevel modeling.
RESULTS: Baseline CRP levels were higher among participants who developed diabetes (median (interquartile range) 1.44 (2.39) vs 0.78 (1.21) mg/l) or fatal CVD (1.49 (2.47) vs 0.84 (1.30) mg/l) compared with controls (both P<0.0001). In models adjusted for age, sex, body mass index, ethnicity, and employment grade, CRP levels increased with time among both incident diabetes cases and controls (P<0.0001), but this increase was less steep for cases group (P<0.05). CRP levels followed increasing linear trajectories in fatal cardiovascular cases and controls (P<0.0001) with no slope difference between the groups.
CONCLUSIONS: CRP levels were higher among those who subsequently developed diabetes or died from CVD. For type 2 diabetes, age-related increase in CRP levels was less steep in the cases group than in controls, whereas for fatal CVD these trajectories were parallel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20573938     DOI: 10.1530/EJE-10-0277

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  23 in total

1.  Six-year change in high-sensitivity C-reactive protein and risk of diabetes, cardiovascular disease, and mortality.

Authors:  Christina M Parrinello; Pamela L Lutsey; Christie M Ballantyne; Aaron R Folsom; James S Pankow; Elizabeth Selvin
Journal:  Am Heart J       Date:  2015-04-18       Impact factor: 4.749

2.  C-reactive protein concentration predicts mortality in type 2 diabetes: the Diabetes Heart Study.

Authors:  A J Cox; S Agarwal; D M Herrington; J J Carr; B I Freedman; D W Bowden
Journal:  Diabet Med       Date:  2012-06       Impact factor: 4.359

3.  The Relationship Between Religious and Psychospiritual Measures and an Inflammation Marker (CRP) in Older Adults Experiencing Life Event Stress.

Authors:  Gail Ironson; Aurelie Lucette; Emily Hylton; Kenneth I Pargament; Neal Krause
Journal:  J Relig Health       Date:  2018-08

4.  Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.

Authors:  Burton E Sobel; Regina M Hardison; Saul Genuth; Maria M Brooks; Robert D McBane; David J Schneider; Richard E Pratley; Kurt Huber; Robert Wolk; Ashok Krishnaswami; Robert L Frye
Journal:  Circulation       Date:  2011-07-18       Impact factor: 29.690

5.  Maternal experiences of ethnic discrimination and child cardiometabolic outcomes in the Study of Latino Youth.

Authors:  Natalie Slopen; Garrett Strizich; Simin Hua; Linda C Gallo; David H Chae; Naomi Priest; Matthew J Gurka; Shrikant I Bangdiwala; Julia I Bravin; Earle C Chambers; Martha L Daviglus; Maria M Llabre; Mercedes R Carnethon; Carmen R Isasi
Journal:  Ann Epidemiol       Date:  2019-03-28       Impact factor: 3.797

6.  Impact of clinical and procedural factors upon C reactive protein dynamics following transcatheter aortic valve implantation.

Authors:  Neil Ruparelia; Vasileios F Panoulas; Angela Frame; Ben Ariff; Nilesh Sutaria; Michael Fertleman; Jonathan Cousins; Jon Anderson; Colin Bicknell; Andrew Chukwuemeka; Sayan Sen; Iqbal S Malik; Antonio Colombo; Ghada W Mikhail
Journal:  World J Cardiol       Date:  2016-07-26

7.  Soluble CD163, adiponectin, C-reactive protein and progression of dysglycaemia in individuals at high risk of type 2 diabetes mellitus: the ADDITION-PRO cohort.

Authors:  Pia Deichgræber; Daniel R Witte; Holger J Møller; Mette V Skriver; Bjørn Richelsen; Marit E Jørgensen; Nanna B Johansen; Annelli Sandbæk
Journal:  Diabetologia       Date:  2016-08-19       Impact factor: 10.122

8.  [Neutrophil to lymphocyte ratio as a predictor for type 2 diabetes mellitus in patients with chronic obstructive pulmonary disease: a cohort study of 404 cases].

Authors:  Tao Ye; Yin Yang; Kai Wang; Mei Wang; Jia Sun; Yue DU; Xin Chen
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-10-20

9.  A large multi-centre European study validates high-sensitivity C-reactive protein (hsCRP) as a clinical biomarker for the diagnosis of diabetes subtypes.

Authors:  G Thanabalasingham; N Shah; M Vaxillaire; T Hansen; T Tuomi; D Gašperíková; M Szopa; E Tjora; T J James; P Kokko; F Loiseleur; E Andersson; S Gaget; B Isomaa; N Nowak; H Raeder; J Stanik; P R Njolstad; M T Malecki; I Klimes; L Groop; O Pedersen; P Froguel; M I McCarthy; A L Gloyn; K R Owen
Journal:  Diabetologia       Date:  2011-08-04       Impact factor: 10.122

10.  Linking discrimination and sleep with biomarker profiles: An investigation in the MIDUS study.

Authors:  Tiffany Yip; Mingzhang Chen; Yijie Wang; Natalie Slopen; David Chae; Naomi Priest; David Williams
Journal:  Compr Psychoneuroendocrinol       Date:  2020-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.